Compare Cisco Systems Inc (CSCO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Incyte Corporation — how do they compare? Cisco Systems Inc trades at $118.39 (market cap $452.96B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Cisco Systems Inc is far larger — about 19.8× Incyte Corporation's market cap, and Cisco Systems Inc pays a 1.46% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and Incyte Corporation for 33 Days on average.
| CSCO | INCY | |
|---|---|---|
Market Cap | $452.96B | $22.85B |
Volume | 12,951,578 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $130.00 | $129.93 |
52-Week Low | $67.46 | $83.80 |
Typical Hold Time | 86 Days | 33 Days |
Enterprise Value | $466.58B | $18.35B |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $114.89, down 2.13% on the day, amid a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported robust Q2 2026 EPS of $1.22, beating estimates, with revenue growth driven by AI networking demand. Analysts maintain a 51.35% buy rating with a $129.77 consensus target, highlighting multi-year growth potential from AI infrastructure and Splunk integration.
The stock presents a favorable risk-reward profile with solid fundamentals, including a 20.95% net margin and consistent earnings beats. Key risks include competitive pressures in AI security and cyclical IT spending. Upside is supported by strong cash flow and strategic partnerships, though valuation multiples like a 34.5 P/E warrant monitoring amid macroeconomic uncertainties.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
